Clinical Trials Logo

Clinical Trial Summary

The aim of the present study is to compare the efficiency of low FODMAP and SSRD to reduce symptoms in IBS, and to study the mechanisms and consequences of the two diets.

Clinical Trial Description

The investigator will perform a study on 200 subjects with verified irritable bowel syndrome (IBS). Participants will be recruited from the clinic of Gastroenterology or Internal medicine as well as primary health care centers. At the start of the study, participants will complete protocols concerning Rom IV criteria (to validate that the IBS criteria are ful-filled) as well as IBS symptom rating scales irritable bowel syndrome-symptoms severity scores (IBS-SSS) and visual analog scale for irritable bowel syndrome (VAS-IBS). The Item Health Survey 1.0 (distributed by RAND), RAND-36, includes the same items as those in the Short-Form Health Survey (SF-36), and evaluates the quality of Life. SCOFF is a brief questionnaire that asks the five questions about eating disturbances (Do you make yourself Sick because you feel uncomfortably full? Do you worry you have lost Control over how much you eat? Have you recently lost more than One stone in a 3 month period? Do you believe yourself to be Fat when others say you are too thin? Would you say that Food dominates your life?). Participants will be examined by an investigator who will complete protocols of clinical data. Blood and fecal samples will be collected by the investigator. Study participants will thereafter be randomized to receive either low FODMAP (Fermentable, Oligo-, Di-, Mono-saccharides And Polyols) diet (n=100), or a SSRD diet (starch ans sucrose-reduced diet) (n=100). After 4 weeks of dietary intervention, there will be a follow-up where blood and fecal samples are once again collected. At this point in time, participants will also fill in IBS symptom rating scales again. The participants are then free to eat whatever they want to, and another 5 months later, they will be examined again, the same protocols will be completed, and blood and fecal samples are collected. The investigator will use samples from baseline, 4 weeks and 6 months, for genetic/epigenetic (including genomic-wide association studies), metabolomics, proteomics, nutritional data, gut microbiota, and inflammatory parameter analyses. Statistics The investigator will use Mann-Whitney U-test and Wilcoxon test to study differences in the above-mentioned parameters between the two treatment groups, as well as before and after dietary intervention, respectively. For analyses of genetic/epigenetics, metabolomics, proteomics, and microbiota, the investigator will use bioinformatics and biostatistics. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT05192603
Study type Interventional
Source Region Skane
Contact Bodil Ohlsson, Professor
Phone +46+40332323
Email [email protected]
Status Not yet recruiting
Phase N/A
Start date March 1, 2022
Completion date March 31, 2029

See also
  Status Clinical Trial Phase
Recruiting NCT05118243 - Innovative Tools to Produce Legume-based Foods for Increased Consumer Acceptance N/A
Completed NCT04422327 - The Impact of a Combination of Bifidobacterium Longum 35624® and 1714™ Strains in Adults With Irritable Bowel Syndrome Phase 1/Phase 2
Recruiting NCT05178017 - Lifestyle Eating and Performance (LEAP) Program for the Treatment of Irritable Bowel Syndrome (IBS) N/A
Completed NCT05197413 - Study to Evaluate the Efficacy of Arrae's Bloat & Calm Alchemy Capsules to Reduce Bloating, Heartburn and Gas, and Alleviate the Intensity of IBS Symptoms N/A
Recruiting NCT03131414 - The IMAGINE-SPOR CIHR Chronic Disease Network
Completed NCT03333291 - Fecal Transplantation in Patients With IBS N/A
Active, not recruiting NCT03449628 - L. Casei DG® in Patients With Irritable Bowel Syndrome. N/A
Not yet recruiting NCT05054309 - A Trial to Evaluate the Effects of Bifidobacterium Longum NCC3001 on Intestinal and Psychological Symptoms in Subjects With Irritable Bowel Syndrome N/A
Recruiting NCT04760353 - The Effect of a Probiotic Mixture in Obese Patients With Irritable Bowel Syndrome N/A
Recruiting NCT04217733 - Ethosuximide and Pentoxifylline in the Treatment of Abdominal Pain Related to Irritable Bowel Syndrome Phase 3
Completed NCT03178877 - The Prevalence of Irritable Bowel Syndrome Using Rome IV Criteria in Medical Student and The Related Factors N/A
Enrolling by invitation NCT03948854 - Implementing a Low FODMAP Diet in Irritable Bowel Syndrome Patients N/A
Completed NCT04898257 - Effect of Lactibiane Tolerance® to Treat Leaky Gut in Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D)Patients N/A
Recruiting NCT04074421 - Effects of Continuous Treatment With Rifaximin and Probiotics on the Gut Microbiota of Patients With IBS-D Phase 4
Completed NCT04348760 - Study of Inflammatory Markers and Symptom Severity in Personalized Nutritional Intervention in IBS N/A
Recruiting NCT03555188 - TReatment of Irritable Bowel Syndrome With Diarrhoea Using Titrated ONdansetron Trial Phase 3
Completed NCT04543474 - Treatment Efficacy of Low FODMAP Versus Low Lactose Diet in IBS Patients N/A
Recruiting NCT04060121 - Efficacy of Psychological Therapies in Patients With Functional Bowel Disorders
Recruiting NCT04129762 - Effect of a Diet Without Non-caloric Sweeteners on Gastrointestinal Symptoms in Patients With IBS and Dyspepsia N/A
Completed NCT04817683 - Study on the Relationship Between Mobile Phone Addiction and Functional Gastrointestinal Disorders